IL6 and fungal infectious disease: Tocilizumab, another IL-6 antibody, was found to be safe, but it showed an increase in the incidence of adverse infectious events such as bacterial and fungal infections with no better outcomes with 400 mg dose compared with patients treated with a single dose of tocilizumab 400 mg [20].